Found 10 matching trials
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma PHASE2 Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian ...
Show More Location
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma N/A This study is conducted to evaluate the efficacy, prognosis, adverse effect...
Show More Location
The Second Affiliated Hospital of Fujian Medical University
Learn More & Join Trial
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors PHASE1 To evaluate the safety and tolerability of IBI3005 combination therapy in p...
Show More Location
SunYat-sen University Cancer Center
Learn More & Join Trial
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma PHASE2 Conversion therapy for unresectable intermediate-advanced hepatocellular ca...
Show More Location
Tianjin Cancer Hospital Airport Hospital
Learn More & Join Trial
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies) PHASE2 This study investigates the efficacy and safety of sintilimab in combinatio...
Show More Location
Multiple Locations
Learn More & Join Trial
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC PHASE2 To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemot...
Show More Location
Tianjin Medical University Cancer Institute & Hospital
Learn More & Join Trial
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma N/A The aim of this study is to the efficacy, prognosis, adverse effects, and f...
Show More Location
The Second Affiliated Hospital of Fujian Medical University
Learn More & Join Trial
CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer PHASE2 Neoadjuvant chemotherapy has been recommended by a series of treatment guid...
Show More Status
Active Not Recruiting
Location
West China Hospital, Sichuan University
Learn More & Join Trial
Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma PHASE2 A randomized controlled, phase II clinical trial is designed to compare the...
Show More Location
Tianjin Medical University Cancer Institute & Hospital
Learn More & Join Trial
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma PHASE2 This is a single-arm, exploratory study to evaluate the efficacy and safety...
Show More Location
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Learn More & Join Trial